Early Detection Research Network

IGF2

Aliases:
This biomarker is also known as:
  • C11orf43,
  • insulin-like growth factor 2 (somatomedin A),
  • FLJ44734,
  • INSIGF,
  • FLJ22066,
  • PP1446,
  • Insulin-like growth factor II,
  • pp9974,
  • chromosome 11 open reading frame 43,
  • Somatomedin-A,
  • IGF2,
  • IGF-II,

Description…

IGF2 is a member of the insulin family of polypeptide growth factors that is involved in development and growth. The IGF2 gene is an imprinted gene and is expressed only from the paternally inherited allele. It is a candidate gene for eating disorders. There is a read-through, INS-IGF2, which aligns to this gene at the 3' region and to the upstream INS gene at the 5' region. Alternatively spliced transcript variants, encoding either the same or different isoform, have been found for this gene. IGF2 is influenced by placental lactogen and may play a role in fetal development.

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Curated
Type: Protein
HGNC Name: IGF2

The following organs have data associated with this biomarker…

Attributes

Phase: Three
QA State: Curated

Overview

Overexpression of the imprinted insulin-like growth factor-II (IGF2) is a prominent characteristic of gynecologic malignancies. Elevated IGF2 expression is a frequent event in serous ovarian cancer and this occurs in the absence of IGF2 loss of imprinting (LOI).

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. IGF2 alone was not a strong predictor.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.